What causes an elevated International Normalized Ratio (INR) in a patient who is not taking anticoagulant medications?

Elevated INR in Patients Not on Anticoagulants

An elevated INR in patients not taking anticoagulants most commonly results from vitamin K deficiency, liver disease, or direct oral anticoagulants (DOACs) that may not have been disclosed—these three etiologies account for the vast majority of cases and require distinctly different management approaches. 1

Primary Causes

Vitamin K Deficiency Pattern

The most common reversible cause shows characteristic laboratory findings 1:

• Low Factor VII, Factor X, Protein C, and Protein S levels
• Normal or near-normal Factor V and fibrinogen
• Responds to vitamin K administration within 24 hours 2

Common clinical scenarios include:

• Malnutrition or poor nutritional intake 3
• Antibiotic use (particularly cefazolin and other cephalosporins with N-methylthiotetrazole side chains) 3
• Gastrointestinal factors affecting vitamin K absorption 2
• Critical illness with inadequate dietary intake 1

Liver Disease Pattern

Hepatic dysfunction produces a distinct coagulation profile 1:

• Low Factor V (key distinguishing feature from vitamin K deficiency)
• Low or normal fibrinogen
• High Factor VIII (acute phase reactant)
• Low levels of anticoagulant proteins (Protein C, Protein S)

Critical caveat: The INR was never validated for assessing bleeding risk in liver disease patients 2. The INR does not predict bleeding in cirrhosis and should not guide plasma transfusion decisions 2. A study of 48 ICU patients found 17 had a liver disease pattern causing elevated INR 1.

Undisclosed Anticoagulant Use

Direct oral anticoagulants (DOACs) can significantly elevate INR 1, 4:

• Anti-Xa activity >0.01 IU/mL indicates DOAC presence
• Apixaban can cause extreme INR elevations (median 1.4-1.7, but cases >20 reported) 4
• Particularly problematic in patients with renal impairment 4

Less Common but Important Causes

Drug-Laboratory Interactions

False elevations without true coagulopathy 5, 6:

• Daptomycin interferes with specific PT/INR reagents 6
• Hemodialysis patients have 9.6-fold increased risk of falsely elevated INR 5
• Confirmed by normal thromboelastography (TEG) despite elevated INR 6

Critical Illness and Comorbidities

In elderly hospitalized patients, prolonged INR without obvious cause 7:

• Associated with dementia, pressure sores, need for assisted feeding
• Lower serum albumin levels
• Predicts 30-day mortality (RR 1.67,95% CI 1.07-2.60) 7
• 67% experienced bleeding and 74% died in one study 8

Diagnostic Approach

Obtain these specific tests immediately:

1. Factor VII, Factor X, Factor V levels to distinguish vitamin K deficiency from liver disease 1
2. Fibrinogen and Factor VIII for pattern recognition 1
3. Anti-Xa activity to detect undisclosed DOACs 1
4. Liver function tests (bilirubin, transaminases, albumin) 8
5. Medication reconciliation focusing on antibiotics, particularly cephalosporins 3

Management Based on Etiology

For Vitamin K Deficiency (Most Common)

• Oral vitamin K 2-5 mg reduces INR within 24 hours 2
• Additional 1-2 mg if INR remains elevated at 24 hours 2
• Avoid plasma transfusion—no evidence of benefit for INR <2.0 2

For Liver Disease

• Do not transfuse plasma prophylactically to correct INR 2
• INR does not predict bleeding risk in cirrhosis 2
• Prothrombin complex concentrates (PCCs) associated with 5.5% thromboembolism rate 2

For Severe Elevation (INR >9) Without Bleeding

• Vitamin K 3-5 mg orally 2
• Monitor closely; repeat vitamin K as necessary 2
• Withholding warfarin or vitamin K alone may be ineffective within 24 hours in hospitalized patients 8

For Active Bleeding

• Plasma infusion immediately drops INR (to ~2.4) 8
• Consider prothrombin complex concentrate for life-threatening bleeding 2
• Vitamin K 10 mg IV slow infusion 2

Critical Pitfalls to Avoid

Do not assume INR elevation indicates bleeding risk in non-warfarin patients 2. The INR was designed and validated exclusively for monitoring vitamin K antagonist therapy 2. A systematic review of 79 studies found weak or no association between INR and bleeding in patients not on warfarin 2.

Do not routinely transfuse plasma for INR <2.0—there is no high-quality evidence of benefit 2. Plasma transfusion carries definite harms, enormous costs, and dubious gains 2.

Consider false elevation in hemodialysis patients or those receiving daptomycin before aggressive intervention 5, 6. Confirm with TEG if available 6.

In elderly patients with unexplained INR elevation, recognize this as a marker of severe illness with high mortality risk rather than simply a coagulation abnormality requiring correction 7.